For in vitro use only!
Shipping: shipped at ambient temperature
Storage Conditions: store at -20 °C
avoid freeze/thaw cycles
Shelf Life: 12 months
Molecular Formula: LSNLYHQGKFLQTFCGSPLYRRR
Molecular Weight: 2785 g/mol
Purity: 85 - 90 % (HPLC)
Form: lyophilized (reconstitution in ddH2O)
The synthetic peptide LSNLYHQGKFLQTFCGSPLY-RRR can be used as a substrate for LKB1 in in vitro kinase assays. It is phosphorylated by the LKB1:STRAD:MO25 complex with a Km of 0.15 mM and a Vmax of 86.8 nmol/min/mg.
Mutations in the widely expressed LKB1 protein kinase in humans result in a disorder termed Peutz-Jeghers syndrome (PJS), which predisposes to a wide spectrum of benign and malignant tumors.
The LKB1 tumour suppressor kinase, in complex with the pseudokinase STRAD and the scaffolding protein MO25, phosphorylates and activates AMP-activated protein kinase (AMPK). A total of 12 human kinases (NUAK1, NUAK2, BRSK1, BRSK2, QIK, QSK, SIK, MARK1, MARK2, MARK3, MARK4 and MELK) are related to AMPK. LKB1 can phosphorylate the T-loop of all the members of this subfamily, apart from MELK, increasing their activity 450-fold. LKB1 catalytic activity and the presence of MO25 and STRAD are required for activation.
Lizcano et al. (2004) LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 23:833.